drugset / Trial / NCT05071417
Effect Of Semaglutide In Coronary Atheroma Plaque
Phase 3
Unknown
120 enrolled
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this trial is to evaluate the effect of Semaglutide on the burden of coronary atherosclerosis, based on the change in Percent Atheroma Volume (PAV) by quantifying atheroma plaque throughout the coronary tree based on the analysis of CCTA in asymptomatic subjects with T2D in optimized and stable treatment with Semaglutide.
Timeline
- Start
- 2021-11
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 0.5 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 1 mg | Subcutaneous |